Sentiment-Signal
19,5
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 28.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 21.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Unternehmen & Branche
| Name | Apogee Therapeutics, Inc. |
|---|---|
| Ticker | APGE |
| CIK | 0001974640 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,81 Mrd. USD |
| Beta | 1,03 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -255,843,000 | -4.22 | 937,134,000 | ||
| 2025-09-30 | 10-Q | -65,021,000 | -1.11 | 626,159,000 | ||
| 2025-06-30 | 10-Q | -66,096,000 | -1.13 | 657,772,000 | ||
| 2025-03-31 | 10-Q | -55,339,000 | -0.95 | 714,162,000 | ||
| 2024-12-31 | 10-K | -182,146,000 | -3.30 | 753,951,000 | ||
| 2024-09-30 | 10-Q | -49,018,000 | -0.86 | 776,286,000 | ||
| 2024-06-30 | 10-Q | -33,816,000 | -0.60 | 800,657,000 | ||
| 2024-03-31 | 10-Q | -32,094,000 | -0.64 | 823,659,000 | ||
| 2023-12-31 | 10-K | -83,985,000 | -3.36 | 401,404,000 | ||
| 2023-09-30 | 10-Q | -20,840,000 | -0.51 | 426,421,000 | ||
| 2023-06-30 | 10-Q | -18,885,000 | -3.78 | 130,667,000 | ||
| 2023-03-31 | 10-Q | -12,525,000 | -2.51 | |||
| 2022-12-31 | 10-K | -39,785,000 | -16.16 | 152,055,000 | ||
| 2022-09-30 | 10-Q | -19,657,000 | -9.46 | |||
| 2022-06-30 | 10-Q | -1,816,000 | -1.45 | |||
| 2022-03-31 | 10-Q | -4,305,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2,000 | 90.00 | -180,000.00 | -54,8% | |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -17,800 | 82.48 | -1,468,144.00 | -446,7% | |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -2,000 | 83.26 | -166,520.00 | -50,7% | |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 85.00 | -17,000.00 | -5,2% | |
| 2026-04-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -900 | 84.46 | -76,014.00 | -23,1% | |
| 2026-04-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1,100 | 85.46 | -94,006.00 | -28,6% | |
| 2026-04-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2,702 | 85.33 | -230,561.66 | -70,1% | |
| 2026-04-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2,698 | 84.31 | -227,468.38 | -69,2% | |
| 2026-04-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -100 | 85.89 | -8,589.00 | -2,6% | |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -8,219 | 74.83 | -615,027.77 | -187,1% | |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -8,363 | 74.29 | -621,287.27 | -189,0% | |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -3,418 | 75.86 | -259,289.48 | -78,9% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -300 | 69.43 | -20,829.00 | -6,3% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -994 | 70.45 | -70,027.30 | -21,3% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -406 | 71.66 | -29,093.96 | -8,9% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -300 | 68.27 | -20,481.00 | -6,2% | |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -7,551 | 63.73 | -481,225.23 | -146,4% | |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -11,494 | 62.96 | -723,662.24 | -220,2% | |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -955 | 64.99 | -62,065.45 | -18,9% | |
| 2026-02-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -792 | 65.21 | -51,646.32 | -15,7% | |
| 2026-02-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -100 | 66.89 | -6,689.00 | -2,0% | |
| 2026-02-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1,108 | 66.15 | -73,294.20 | -22,3% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -2,374 | 81.00 | -192,294.00 | -58,5% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -8,476 | 79.82 | -676,554.32 | -205,8% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -5,386 | 83.16 | -447,899.76 | -136,3% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -470 | 83.79 | -39,381.30 | -12,0% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1,854 | 82.41 | -152,788.14 | -46,5% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1,440 | 78.64 | -113,241.60 | -34,5% | |
| 2026-01-06 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2,000 | 80.00 | -160,000.00 | -48,7% | |
| 2026-01-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -4,080 | 75.20 | -306,816.00 | -93,3% | |
| 2026-01-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1,920 | 74.13 | -142,329.60 | -43,3% | |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -9,435 | 74.88 | -706,492.80 | -214,9% | |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -10,005 | 75.79 | -758,278.95 | -230,7% | |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -560 | 76.58 | -42,884.80 | -13,0% | |
| 2025-12-04 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 75.01 | -3,000,400.00 | -912,8% | |
| 2025-12-04 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1,500 | 75.00 | -112,500.00 | -34,2% | |
| 2025-11-14 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2,000 | 65.00 | -130,000.00 | -39,6% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -100 | 64.52 | -6,452.00 | -2,0% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1,786 | 63.89 | -114,107.54 | -34,7% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -14,774 | 63.14 | -932,830.36 | -283,8% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -3,340 | 61.93 | -206,846.20 | -62,9% | |
| 2025-11-11 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1,000 | 60.00 | -60,000.00 | -18,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.